Jiangsu Hengrui Pharmaceuticals (01276.HK): Insulin Sudelidec Injection Approved for Marketing by NMPA

NewTimeSpace News: On 29 July 2026, Jiangsu Hengrui Pharmaceuticals (01276.HK) issued an announcement. Insulin Sudelidec Injection, the self-developed Category 1 therapeutic biological product of the Company, was approved for marketing by NMPA. Its specifications include 3mL:300 units (prefilled pen) and 3mL:300 units (pen cartridge), and the drug is a prescription medicine.

According to the announcement, this drug is China’s first domestically self-developed long-acting insulin analogue, featuring stable onset of action, long duration of efficacy, and low risk of nocturnal hypoglycemia. The cumulative R&D investment for this project reached approximately RMB 544.3 million.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.